La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Hologic Croissance future

Future contrôle des critères 1/6

Hologic devrait augmenter ses bénéfices et son chiffre d'affaires de 10.7% et de 5.4% par an respectivement. Le BPA devrait croître de de 12.5% par an. Le rendement des capitaux propres devrait être 18% dans 3 ans.

Informations clés

10.7%

Taux de croissance des bénéfices

12.5%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.4%
Taux de croissance des recettes	5.4%
Rendement futur des capitaux propres	18.0%
Couverture par les analystes	Good
Dernière mise à jour	16 Aug 2024

Mises à jour récentes de la croissance future

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Feb 06

Recent updates

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Jul 21

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Jun 20

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Sep 28

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Aug 29

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 31

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Jul 18

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Jun 21

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

May 22

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Apr 25

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Apr 10

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Mar 13

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Feb 14

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Jan 18

Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?

Jan 03

Shareholders Would Enjoy A Repeat Of Hologic's (NASDAQ:HOLX) Recent Growth In Returns

Dec 02

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:HOLX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2026	4,502	969	1,169	1,189	14
9/30/2025	4,253	875	1,063	1,140	17
9/30/2024	4,020	794	1,005	1,048	17
6/29/2024	3,988	702	1,015	1,177	N/A
3/30/2024	3,961	467	949	1,104	N/A
12/30/2023	3,969	515	859	1,018	N/A
9/30/2023	4,030	456	901	1,051	N/A
7/1/2023	4,038	484	832	961	N/A
4/1/2023	4,057	753	841	959	N/A
12/31/2022	4,466	990	1,696	1,815	N/A
9/24/2022	4,863	1,302	1,999	2,126	N/A
6/25/2022	5,226	1,512	2,283	2,423	N/A
3/26/2022	5,392	1,552	2,598	2,755	N/A
12/25/2021	5,494	1,716	2,068	2,245	N/A
9/25/2021	5,632	1,872	2,146	2,330	N/A
6/26/2021	5,663	2,038	2,108	2,307	N/A
3/27/2021	5,317	1,907	1,677	1,867	N/A
12/26/2020	4,536	1,384	1,263	1,433	N/A
9/26/2020	3,776	1,115	740	897	N/A
6/27/2020	3,295	497	573	702	N/A
3/28/2020	3,325	453	518	643	N/A
12/28/2019	3,387	84	536	659	N/A
9/28/2019	3,367	-204	536	650	N/A
6/29/2019	3,315	-30	520	634	N/A
3/30/2019	3,287	-11	596	705	N/A
12/29/2018	3,258	-419	562	668	N/A
9/29/2018	3,218	-111	627	733	N/A
6/30/2018	3,207	-79	560	667	N/A
3/31/2018	3,189	-132	N/A	21	N/A
12/30/2017	3,116	1,076	N/A	8	N/A
9/30/2017	3,059	756	N/A	8	N/A
7/1/2017	2,983	765	N/A	70	N/A
4/1/2017	2,894	790	N/A	729	N/A
12/31/2016	2,872	332	N/A	796	N/A
9/24/2016	2,833	331	N/A	798	N/A
6/25/2016	2,809	264	N/A	802	N/A
3/26/2016	2,785	208	N/A	797	N/A
12/26/2015	2,747	187	N/A	804	N/A
9/26/2015	2,705	132	N/A	797	N/A
6/27/2015	2,641	135	N/A	685	N/A
3/28/2015	2,580	116	N/A	601	N/A
12/27/2014	2,549	52	N/A	513	N/A
9/27/2014	2,531	17	N/A	508	N/A
6/28/2014	2,477	-1,125	N/A	455	N/A
3/29/2014	2,470	-1,147	N/A	543	N/A
12/28/2013	2,458	-1,181	N/A	488	N/A
9/28/2013	2,492	-1,173	N/A	494	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de HOLX ( 10.7% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de HOLX ( 10.7% par an) devraient croître plus lentement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de HOLX devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de HOLX ( 5.4% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de HOLX ( 5.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de HOLX devrait être faible dans 3 ans ( 18 %).

Hologic Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Consensus EPS estimates fall by 22%

Recent updates

Chairman notifies of intention to sell stock

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Insider recently sold US$200k worth of stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher